CEACAM5 and colorectal carcinoma: This study suggests that Eu NPs-based CD151CD63 assays in combination with glycovariant of CEA and CA125 are more sensitive in distinguishing CRC patient’s serum from benign and healthy controls than conventional CEA biomarkers alone.